| CEO Name | Richard A. Gonzalez |
| Nationality | United States |
| Net Worth Estimation | $90 million |
Richard A. Gonzalez's estimated net worth of around $90 million is primarily attributed to his long tenure as Chairman and CEO of AbbVie Inc., which acquired Allergan plc, and is based on his accumulated stock awards, salary, bonuses, and other executive compensation reported in SEC filings. His holdings in AbbVie's shares and sustained leadership position in the pharmaceutical industry significantly contribute to this valuation.
Richard A. Gonzalez, CEO of Allergan plc (now part of AbbVie Inc.), has an estimated net worth of $90,000,000, which is at the maximum of the provided healthcare CEO net worth range ($10,000,000 to $90,000,000). His net worth represents 100% of the category's maximum estimated CEO net worth.
Business Category: Healthcare
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 90000000 USD
Richard A. Gonzalez Performance in Allergan plc (now part of AbbVie Inc.)
Richard A. Gonzalez, CEO of Allergan plc until its acquisition by AbbVie Inc., demonstrated decisive leadership by spearheading strategic acquisitions and driving innovation in the pharmaceutical sector. His decision-making prioritized expanding Allergan's product portfolio, particularly in aesthetics and eye care, significantly boosting company performance and market value. Under his leadership, Allergan transformed into a global biopharmaceutical leader, culminating in AbbVie's $63 billion acquisition, highlighting his impactful growth strategy.
Latest News
AbbVie Completes Acquisition of Allergan, Diversifying Portfolio and Leadership
AbbVie finalized its $63 billion acquisition of Allergan in May 2020, expanding AbbVie's therapeutic reach into neuroscience and aesthetics, notably with Botox, while CEO Richard A. Gonzalez emphasized the enhanced long-term growth potential and innovation investment this merger enables. Allergan's CEO Brent Saunders joined AbbVie's board, reinforcing leadership continuity as the combined company focuses on diversified revenue beyond Humira.
Source: http://pharmatimes.com/news/abbvie_completes_acquisition_of_allergan_1340086/